Drilldown: Medicines
Appearance
Medicines > onset
:
30–60 min
or
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks)
or
BP and symptomatic LUTS improvement within 1-2 weeks 
:
30–60 min
or
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks)
or
BP and symptomatic LUTS improvement within 1-2 weeks 
Use the filters below to narrow your results.
CNS stimulant (1) ·
NDRI (1) ·
non-stimulant ADHD agent (1) ·
PDE5 Inhibitor (1) ·
Psychostimulant (1) ·
Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism (1) ·
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2)
None (1) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) ·
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
None (1) ·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1) ·
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)
Category B (1) ·
Category C (1) ·
Limited data (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.

